Characterizing Ceftriaxone-induced Urolithiasis and Its Associated Acute Kidney Injury: an Animal Study and Chinese Clinical Systematic Review

Overview

Journal Int Urol Nephrol

Publisher Springer

Specialty Nephrology

Date 2016 Apr 30

PMID 27126355

Citations 6

Authors

Yifan Zhang

Benxiang Ning

Huaijun Zhu

Xiaoming Cong

Leqing Zhou

Qiang Wang

Liming Zhang

Xizhao Sun

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the pathophysiological process of ceftriaxone-induced urolithiasis and its associated acute kidney injury (AKI) based on an animal study and summarize the main clinical characteristics based on a Chinese clinical systematic review.

Materials And Methods: Male Sprague-Dawley rats were randomly divided into five groups of six each according to different treatments including control; ceftriaxone; ceftriaxone with calcium; calcium; and ceftriaxone, calcium with citrate, respectively. The 24-h urine volume, serum creatinine (Scr) and blood urea nitrogen (BUN) were measured; kidney histological examination and stone analysis were performed. Systematic searches of the Chinese Knowledge Database were conducted for reports on ceftriaxone-induced urolithiasis and AKI. The eligibility of each full-text publication was accessed, and qualified data were extracted and reviewed.

Results: Kidney stones and a significantly low 24-h urine volume with increased high Scr and BUN levels were found in the group that received ceftriaxone combined with calcium. Citrate was able to inhibit these biochemical changes and stone formations. A total of 161 qualified patients were included in the Chinese clinical systematic review: The proportion of ceftriaxone-induced urolithiasis was 21.1, 19.3, 19.3, 39.1 and 1.2 % for ages <3, 3-6, 7-17, 18-60 and >60 years. 72.7 % developed acute kidney injury eventually.

Conclusion: Ceftriaxone-induced urolithiasis was associated with a high risk of AKI. The pathophysiological process may be related to urinary obstruction and crystalline nephropathy. Citrate was able to inhibit stone formation and prevent further kidney injury.

Citing Articles

Nephrotoxicity of Amoxicillin and Third-Generation Cephalosporins: An Updated Review.

Garnier A, Drablier G, Briet M, Augusto J Drug Saf. 2023; 46(8):715-724.

PMID: 37310614 DOI: 10.1007/s40264-023-01316-1.

The Risk and Clinical Implications of Antibiotic-Associated Acute Kidney Injury: A Review of the Clinical Data for Agents with Signals from the Food and Drug Administration's Adverse Event Reporting System (FAERS) Database.

Clifford K, Selby A, Reveles K, Teng C, Hall 2nd R, McCarrell J Antibiotics (Basel). 2022; 11(10).

PMID: 36290024 PMC: 9598234. DOI: 10.3390/antibiotics11101367.

Ceftriaxone Calcium Crystals Induce Acute Kidney Injury by NLRP3-Mediated Inflammation and Oxidative Stress Injury.

Yifan Z, Benxiang N, Zheng X, Luwei X, Liuhua Z, Yuzheng G Oxid Med Cell Longev. 2020; 2020:6428498.

PMID: 32695257 PMC: 7368937. DOI: 10.1155/2020/6428498.

Drug-Induced Urolithiasis in Pediatric Patients.

Sighinolfi M, Eissa A, Bevilacqua L, Zoeir A, Ciarlariello S, Morini E Paediatr Drugs. 2019; 21(5):323-344.

PMID: 31541411 DOI: 10.1007/s40272-019-00355-5.

Anti-Inflammatory and Immune Regulatory Actions of Naja naja atra Venom.

Wang S, Qin Z Toxins (Basel). 2018; 10(3).

PMID: 29495566 PMC: 5869388. DOI: 10.3390/toxins10030100.

References

Akl K, Masri A, Hjazeen M . Acute urine retention induced by ceftriaxone. Saudi J Kidney Dis Transpl. 2011; 22(6):1226-8. View

Grasberger H, Otto B, Loeschke K . Ceftriaxone-associated nephrolithiasis. Ann Pharmacother. 2000; 34(9):1076-7. DOI: 10.1345/aph.19363. View

Schmutz H, Detampel P, Buhler T, Buttler A, Gygax B, Huwyler J . In vitro assessment of the formation of ceftriaxone-calcium precipitates in human plasma. J Pharm Sci. 2011; 100(6):2300-10. DOI: 10.1002/jps.22466. View

Shen X, Liu W, Fang X, Jia J, Lin H, Xu M . Acute kidney injury caused by ceftriaxone-induced urolithiasis in children: a single-institutional experience in diagnosis, treatment and follow-up. Int Urol Nephrol. 2014; 46(10):1909-14. DOI: 10.1007/s11255-014-0742-x. View

Araz N, Okan V, Demirci M, Araz M . Pseudolithiasis due to ceftriaxone treatment for meningitis in children: report of 8 cases. Tohoku J Exp Med. 2007; 211(3):285-90. DOI: 10.1620/tjem.211.285. View

Cochat P, Cochat N, Jouvenet M, Floret D, Wright C, Martin X . Ceftriaxone-associated nephrolithiasis. Nephrol Dial Transplant. 1990; 5(11):974-6. DOI: 10.1093/ndt/5.11.974. View

Li N, Zhou X, Yuan J, Chen G, Jiang H, Zhang W . Ceftriaxone and acute renal failure in children. Pediatrics. 2014; 133(4):e917-22. DOI: 10.1542/peds.2013-2103. View

Markowitz G, Perazella M . Drug-induced renal failure: a focus on tubulointerstitial disease. Clin Chim Acta. 2004; 351(1-2):31-47. DOI: 10.1016/j.cccn.2004.09.005. View

Lin W, Lai M, Chen H, Ho C, Man K, Shen J . Protective effect of Flos carthami extract against ethylene glycol-induced urolithiasis in rats. Urol Res. 2012; 40(6):655-61. DOI: 10.1007/s00240-012-0472-4. View

10.

Mohkam M, Karimi A, Gharib A, Daneshmand H, Khatami A, Ghojevand N . Ceftriaxone associated nephrolithiasis: a prospective study in 284 children. Pediatr Nephrol. 2007; 22(5):690-4. DOI: 10.1007/s00467-006-0401-2. View

11.

Klesel N, Limbert M, Seeger K, Seibert G, Winkler I, Schrinner E . Cefodizime, an aminothiazolylcephalosporin. II. Comparative studies on the pharmacokinetic behavior in laboratory animals. J Antibiot (Tokyo). 1984; 37(8):901-9. DOI: 10.7164/antibiotics.37.901. View

12.

Guan N, Fan Q, Ding J, Zhao Y, Lu J, Ai Y . Melamine-contaminated powdered formula and urolithiasis in young children. N Engl J Med. 2009; 360(11):1067-74. DOI: 10.1056/NEJMoa0809550. View

13.

Daudon M, Jungers P . Drug-induced renal calculi: epidemiology, prevention and management. Drugs. 2004; 64(3):245-75. DOI: 10.2165/00003495-200464030-00003. View

14.

Prince J, Senac Jr M . Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis in a child. Pediatr Radiol. 2003; 33(9):648-51. DOI: 10.1007/s00247-003-0963-0. View

15.

Chutipongtanate S, Thongboonkerd V . Ceftriaxone crystallization and its potential role in kidney stone formation. Biochem Biophys Res Commun. 2011; 406(3):396-402. DOI: 10.1016/j.bbrc.2011.02.053. View

16.

Tang X, Lieske J . Acute and chronic kidney injury in nephrolithiasis. Curr Opin Nephrol Hypertens. 2014; 23(4):385-90. PMC: 4096690. DOI: 10.1097/01.mnh.0000447017.28852.52. View

17.

Mason J, Olbricht C, Takabatake T, Thurau K . The early phase of experimental acute renal failure. I. Intratubular pressure and obstruction. Pflugers Arch. 1977; 370(2):155-63. DOI: 10.1007/BF00581689. View

18.

Lozanovski V, Gucev Z, Avramoski V, Kirovski I, Makreski P, Tasic V . Ceftriaxone associated urolithiasis in a child with hypercalciuria. Hippokratia. 2011; 15(2):181-3. PMC: 3209686. View

19.

Avci Z, Koktener A, Uras N, Catal F, Karadag A, Tekin O . Nephrolithiasis associated with ceftriaxone therapy: a prospective study in 51 children. Arch Dis Child. 2004; 89(11):1069-72. PMC: 1719698. DOI: 10.1136/adc.2003.044156. View

20.

Li Z, Li H, Chen H, Li H, Zhang P, Wang Z . Anuria and abdominal pain induced by ceftriaxone-associated ureterolithiasis in adults. Int Urol Nephrol. 2012; 45(1):73-6. DOI: 10.1007/s11255-012-0330-x. View